VolitionRx to Host Virtual Investor Event on Sepsis Management
VolitionRx Limited (NYSE AMERICAN: VNRX), a leading epigenetics company, is excited to announce a virtual investor event focusing on innovative approaches to sepsis management. This event is set for an upcoming Friday morning and aims to present vital information on the Nu.Q® NETs biomarker.
Understanding Nu.Q® NETs in Sepsis
The event, featuring Dr. Andrew Retter, will delve into the exploration of Nu.Q® NETs H3.1— a groundbreaking biomarker. This novel marker is essential for identifying early mortality risk and organ dysfunction in sepsis patients. Additionally, it serves as an independent predictor for the requirement of renal replacement therapy (RRT), which is critical for patient management.
Clinical Insights and Latest Findings
Recent findings from a large-scale study highlight the significant clinical utility of Nu.Q® NETs in aiding early intervention for patients at critical risk due to sepsis. Dr. Retter is expected to share insights that underscore how this biomarker could transform standard healthcare practices.
Company Progress in Commercialization
During the event, Gael Forterre, the Chief Commercial Officer, will discuss Volition's strategy for commercializing its product line. The focus will range from licensing agreements to direct and indirect sales approaches that strengthen Volition’s market presence.
Future Outlook for Volition
Forterre will also highlight the ongoing efforts to establish a robust commercialization plan. Under his leadership, Volition aims to leverage the extensive range of products developed using the Nu.Q platform, helping to drive awareness and adoption throughout the healthcare sector.
Meet the Experts
Dr. Andrew Retter brings a wealth of experience as a consultant in critical care and the Chief Medical Officer at Volition. Known for his contributions to clinical trials and research, Dr. Retter has published over 50 articles in peer-reviewed journals, emphasizing his commitment to advancing medical technology.
Gael Forterre's Leadership Experience
Gael Forterre, who assumed the role of Chief Commercial Officer in 2021, is passionate about developing a commercialization strategy that ensures effective product reach. His diverse background includes significant roles in investment and leadership, grounded in a strong academic foundation in finance and business.
About VolitionRx
VolitionRx is at the forefront of epigenetic science, dedicated to improving lives through enhanced diagnostic capabilities. The company develops simple, cost-effective blood tests aimed at diagnosing a variety of diseases, including cancers and conditions related to NETosis, particularly sepsis.
Commitment to Early Detection
By focusing research and development efforts primarily in Europe and North America, VolitionRx is paving pathways towards earlier disease detection and treatment monitoring. This proactive approach can potentially extend patient lifespans and improve their overall quality of life, showcasing Volition's mission in the healthcare landscape.
Frequently Asked Questions
When is the virtual investor event by VolitionRx scheduled?
The event is scheduled for an upcoming Friday at 8:00 AM ET.
Who will be presenting at the event?
Dr. Andrew Retter and Gael Forterre will present insights on sepsis management and commercialization strategies.
What is the significance of Nu.Q® NETs?
Nu.Q® NETs H3.1 is a promising biomarker for predicting early mortality and organ dysfunction in sepsis patients.
How can attendees engage during the event?
There will be a live question and answer session following the formal presentations, allowing for audience interaction.
What is VolitionRx's overarching goal?
VolitionRx aims to advance epigenetic science to enable earlier disease detection and ultimately improve patient outcomes.
